Form 4 for PFE Pfizer
Accepted 2021-11-30 00:00:00 ET · period of report 2021-11-26 · accession 0001225208-21-014219 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-11-30 | 2021-11-26 | PFE | SUSMAN SALLY | EVP | S - Sale | $54.52 | -44.3K | 126.2K | -26% | -$2.42M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-26 | S | D | 901 | $54.56 | 129,574 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-26 | S | D | 800 | $54.47 | 130,475 | D | — | — | |
| 3 | Common | Common Stock | 2021-11-26 | S | D | 700 | $54.49 | 131,275 | D | — | — | |
| 4 | Common | Common Stock | 2021-11-26 | S | D | 700 | $54.50 | 131,975 | D | — | — | |
| 5 | Common | Common Stock | 2021-11-26 | S | D | 400 | $54.51 | 132,675 | D | — | — | |
| 6 | Common | Common Stock | 2021-11-26 | S | D | 399 | $54.53 | 133,075 | D | — | — | |
| 7 | Common | Common Stock | 2021-11-26 | S | D | 250 | $54.57 | 133,474 | D | — | — | |
| 8 | Common | Common Stock | 2021-11-26 | S | D | 101 | $54.48 | 133,724 | D | — | — | |
| 9 | Common | Common Stock | 2021-11-26 | S | D | 58 | $54.43 | 133,825 | D | — | — | |
| 10 | Common | Common Stock | 2021-11-26 | S | D | 20,520 | $54.44 | 89,575 | D | — | — | |
| 11 | Common | Common Stock | 2021-11-26 | S | D | 12,370 | $54.64 | 110,095 | D | — | — | |
| 12 | Common | Common Stock | 2021-11-26 | S | D | 3,700 | $54.55 | 122,465 | D | — | — | |
| 13 | Common | Common Stock | 2021-11-26 | S | D | 1,130 | $54.65 | 128,444 | D | — | — | |
| 14 | Common | Common Stock | 2021-11-26 | S | D | 2,279 | $54.45 | 126,165 | D | — | — |